Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CFAP418 (Cilia- and flagella-associated protein 418) is a membrane lipid-binding protein highly expressed in the brain, heart, and retina. It binds specifically to phosphatidic acid (PA) and cardiolipin (CL), lipids involved in membrane biogenesis, mitochondrial integrity, and vesicular trafficking. Disruption of CFAP418 alters membrane lipid composition, disturbs organelle function, and impairs photoreceptor disk morphogenesis. Mutations in the CFAP418 gene lead to inherited retinal degenerations such as retinitis pigmentosa and cone-rod dystrophy, and syndromic ciliopathies like Bardet-Biedl syndrome 21. CFAP418 does not fit classical drug target classes (e.g., receptor or enzyme) and there are currently no known drugs acting directly on this protein. Its primary role is maintaining membrane lipid homeostasis crucial for the function and structural integrity of photoreceptors and other ciliated cells
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cilia- and flagella-associated protein 418 (CFAP418).